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The broad capacity of pluripotent human embryonic stem cells (hESC) to grow and
differentiate demands the development of rapid, scalable, and label-free methods to
separate living cell populations for clinical and industrial applications. Here, we
identify differences in cell stiffness, expressed as cell elastic modulus (CEM), for
hESC versus mesenchymal progenitors, osteoblast-like derivatives, and fibroblasts
using atomic force microscopy and data processing algorithms to characterize the
stiffness of cell populations. Undifferentiated hESC exhibited a range of CEMs
whose median was nearly three-fold lower than those of differentiated cells, infor-
mation we exploited to develop a label-free separation device based on the princi-
ples of tangential flow filtration. To test the device’s utility, we segregated hESC
mixed with fibroblasts and hESC-mesenchymal progenitors induced to undergo
osteogenic differentiation. The device permitted a throughput of 106–107 cells per
min and up to 50% removal of specific cell types per single pass. The level of
enrichment and depletion of soft, pluripotent hESC in the respective channels was
found to rise with increasing stiffness of the differentiating cells, suggesting CEM
can serve as a major discriminator. Our results demonstrate the principle of a scal-
able, label-free, solution for separation of heterogeneous cell populations deriving
from human pluripotent stem cells.VC 2016 AIP Publishing LLC.
[http://dx.doi.org/10.1063/1.4939946]
INTRODUCTION
Stem cell research and regenerative medical treatments are progressing towards the devel-
opment of more complex, cell-based, advanced therapies as an alternative to the use of thera-
peutic proteins. Bio-production and processing of these cell-based products for the clinic, how-
ever, necessitate a re-think of current manufacturing technology. An important aspect in the
manufacturing of any medicinal product is control of the composition of matter to assure its
efficacy and reproducibility of outcomes following its use. This will be especially critical for
the manufacture of stem cell derived cellular products given the potential of the starting cellular
resource to differentiate in uncontrolled manner or contaminate the final end product. This
applies to end products used in vitro, such as in high-throughput screening platforms, as well as
a)N. A. Willoughby and H. Bock contributed equally to this work.
b)Authors to whom correspondence should be addressed. Electronic addresses: N.A.Willoughby@hw.ac.uk, Tel.: þ44 131
451 4377, Fax: þ44 131 451 3129 and paul.desousa@ed.ac.uk, Tel.: þ44 131 242 6646, Fax: þ44 131 242 6201.
c)Current address: School of Materials, University of Manchester, Manchester, United Kingdom.
d)Current address: ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Mawson Institute,
University of South Australia, Adelaide, Australia.
1932-1058/2016/10(1)/014107/16/$30.00 VC 2016 AIP Publishing LLC10, 014107-1
BIOMICROFLUIDICS 10, 014107 (2016)
 This article is copyrighted as indicated in the article. Reuse of AIP content is subject to the terms at: http://scitation.aip.org/termsconditions. Downloaded to  IP:
129.215.87.150 On: Fri, 15 Jan 2016 09:38:46
for in vivo, for cell engraftment to treat degenerative disease or damaged tissues. The broad
capacity of human pluripotent stem cells, as derived from embryos or induced by genetic
manipulation of adult cells, accentuates concern for their usage as source material for the latter,
owing to the risk of a contaminating undifferentiated cell giving rise to benign tumours of dif-
ferentiating cells (i.e., teratomas), or malignant metastatic tumours composed of highly prolifer-
ative cells (i.e., teratocarcinoma). Knowledge and control of the composition of stem cell
derived cell products may also be important to achieve specific therapeutic outcomes, as evi-
denced recently by Van Vliet and coworkers who reported that different subpopulations within
culture expanded bone marrow-derived mesenchymal stromal cells possess unique tissue regen-
erative potential (Lee et al., 2014).
The majority of scalable purification processes used in the production of therapeutic proteins
by the pharmaceutical industry are based on the use of column chromatography to obtain the
desired levels of purity. However, traditional absorption-based column chromatographic techniques
are unlikely to be applicable to cell purification due to the greater size, sensitivity, and complexity
of cells compared to proteins. Currently, the most commonly applied approach to cell purification
in life sciences and small scale clinical applications is largely dependent on the recognition and
selection of cell surface ligands, as commonly achieved by flow cytometric- or magnetic bead-
based sorting. However, these methods are severely constrained by a requirement for cell-specific
ligands (i.e., knowledge, availability, and specificity thereof) and the availability of complementary
probes. Moreover, probes likely remain associated with the cell and/or cell preparation after segre-
gation, the consequences of which are not known, but are generally recognized to risk invoking
immune or toxic responses in patients. Importantly, these ligand-based methods are limited in their
throughput, and in their current form do not constitute scalable strategies to purify the anticipated
cell numbers for pluripotent stem cell-based therapeutic products.
The predicted future reliance of health care on advanced therapy medicinal products
(ATMPs), the new category of “drugs” that are actually cell populations, will create demand
for large-scale cell separation embedded in automated cell culture production platforms.
Worldwide, hundreds of cell-based clinical trials are proposed and currently ongoing (as search-
able on the USA National Institutes of Health clinical trials registry www.clinicaltrials.gov, or
the European counterpart www.clinicaltrialsregister.eu), which, once demonstrated successful
and safe, will warrant production of large quantities of cells according to Good Manufacturing
Practice. In the manufacture of cells for therapy, the current most commonly used large-scale
cell separation in method applied in the context of blood products makes use of biophysical
cell parameters and selects cells on the basis of size and density by means of density gradient
centrifugation. This method is most effective when considering cells of distinctly different den-
sities such as separating enucleated red blood cells from white blood cells. Moreover, though
centrifugation itself is a relatively easily scaled unit operation, scale-up requires a transition
from semi-batch to continuous operation, an operating mode not easily compatible with density
gradients. In addition, physical shear forces on the cells increase as the size of the device
increases, risking damaging sensitive cell products. Thus, there is an urgent need for new cell
separation methods that lend themselves to large-scale use for clinical cell manufacture.
New, alternative cell separation technologies on the basis of biophysical properties have
recently been reported which potentially offer opportunities for a passive (i.e., without exerting
an external force on the cells) and label-free sorting technique (reviewed in Bhagat et al., 2010;
Gonzalez-Gonzalez et al., 2012; Darling and Di Carlo, 2015; and Kunze et al., 2015). Many of
these technologies are based on multiple parameters, often including size, and one or more of
additional properties including density, shape, hydrophobicity, net charge, sedimentation den-
sity, intrinsic hydrodynamic forces, differential magnetic susceptibility of cell (-content), refrac-
tive index, polarisability, membrane properties such as surface charge, cytosol conductivity, and
cell deformability/stiffness. These technologies have mainly been designed as microfluidic devi-
ces, only suitable for small-scale separation. The aim of this study was to develop a novel alter-
native to absorption-based and label-requiring selection methods for stem and derivative cells
that is readily scalable and could be broadly implemented in industrial and therapeutic applica-
tions. Using atomic force microscopy (AFM), we identified variations in cell stiffness related to
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cell phenotype and could identify optimum stages at which pluripotent human embryonic stem
cells (hESC) could be separated from their progeny. Using a separation device based on the
principles of tangential flow filtration (TFF), we demonstrate the proof-of-principle ability to
scalably and selectively enrich or deplete for particular cell populations primarily on the basis
of knowledge of cell stiffness, without reliance on cell labeling with high-affinity probes for
cell specific antigens. Our findings underpin the development of a novel cell-bioprocessing plat-
form to meet the future needs of pluripotent stem cell manufacturing for industrial and clinical
applications.
MATERIALS AND METHODS
Cell culture and differentiation
The use of hESC lines in this project was approved by the Medical Research Council (MRC)
steering committee overseeing the UK Stem Cell Bank. H1-hESCs were licensed from WiCell
(available from the Wisconsin International Stem Cell Bank (www.wicell.org)). To facilitate recog-
nition of cells with an active pluripotency promoter, for some experiments, a transgenic clone of
H1-hESC was used where expression of Green Fluorescent Protein is directly linked to a pluripo-
tency associated promoter (Oct4; H1-Oct4-EGFP cells, WiCell) (Gerrard et al., 2005). Starting
hESC populations used in this study were at passage 60–70. All hESCs were cultured under
feeder-independent conditions in mTeSR1 medium (STEMCELL Technologies) containing 50
U/ml penicillin, 50lg/ml streptomycin, and 2.5lg/ml Fungizone at 37 C, 5% CO2 in air.
Undifferentiated hESCs were grown on MatrigelTM (Becton Dickinson) and routinely passaged by
mechanical scraping following treatment with collagenase IV (200 u/ml in Knockout Dulbecco’s
Modified Eagle Medium (DMEM)). hESC cultures were seeded at a density of approximately 100
000 cells/cm2 and split at a pre- to post-plating ratio of 1:2 wells (i.e., passaging cells from one
well into two new wells). hESC cultures were passaged at 80% confluence every 4–5 days.
Addition of G418 to culture medium (1:1000) allowed selective ablation of Oct4-EGFP transgene
silenced cells, while visual inspection was employed to correlate GFP expression with undifferenti-
ated hESC colony morphology. Human dermal fibroblasts (HDFs) from neonatal foreskin
(Cascade Biologics) were cultured on plastic (Corning), in M106 medium (Invitrogen) supple-
mented with low serum growth supplement (LSGS, 50), at 37 C, 5% CO2 in air.
H1-hESCs were differentiated to a mesenchymal progenitor phenotype (designated hESC-
MP) as reflected by flow cytometric determination of negativity for CD14 and CD34 and detec-
tion of CD105, CD90, CD73, and Stro1, using a method previously developed and validated by
ourselves and others ((De Sousa, 2006; Harkness et al., 2011; and Velugotla et al., 2012). The
method involves plating hESCs (5 105 cells/9.6 cm2) on hyaluronan (HA; also known as hyal-
uronic acid or hyaluronate) (1200 kD; Calbiochem Cat Nr 385908) in a medium that would oth-
erwise support hESC self-renewal (human dermal fibroblast conditioned medium (HDF-CM)
composed of KO-DMEM, 20% Knockout serum replacement (KOSR, Invitrogen), 1mM gluta-
mine, 0.1mM b-mercaptoethanol, and 4 ng/ml bFGF). An HA stock solution for tissue culture
plate coating was produced by solubilizing HA in Phosphate Buffered Saline (PBS) at 10mg/ml
Wells were coated with this HA stock solution at 0.1ml/cm2 for 30min at 4 C, and plates warmed
to room temperature prior to cell plating. Cells were passaged every 5–7 days by collagenase IV
treatment and scraping, as described above. After 10 passages on HA, cells had irreversibly
adopted the hESC-MP phenotype.
For osteogenic differentiation of hESC, H1-hESCs were steered towards the mesenchymal
progenitor phenotype hESC-MP as described above, and then gradually transitioned over 4 days
from the HDF-CM medium to 100% STEMPRO
VR
MSC SFM medium (Life Technology) by
exchange of media mixed in different ratios (100:0; 75:25; 50:50; 25:75, 0:100) at daily inter-
vals. Differentiation of hESC-MP cells towards osteoblasts was carried out on cell culture plates
coated with HA using the StemPro Osteogenesis Differentiation Kit (Life Technology), accord-
ing to manufacturer’s instructions. hESC-MPs cultured in STEMPRO MSC SFM medium
served as negative control. Differentiation lasted 21 days, re-feeding every 2–3 days and pas-
saging every 5–7 days.
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ATOMIC FORCE MICROSCOPY
Cell stiffness was probed by force spectroscopy, i.e., by measuring force versus indentation
curves using AFM (see supplementary material). Subsequent quantitative characterization of
cell stiffness was achieved by fitting the proper form of the Hertz equation (Hertz and Angew,
1881) to the repulsive indentation part of these curves (Kuznetsova et al., 2002 and
Radmacher, 1992). The indentations formed rectangular arrays with pixel sizes between 1 and
18 lm2. Indentation speed was 10 lm/s for both tip approach and retraction at a maximum
indentation force of 2 nN. Typically, all force spectroscopy was completed in approximately
4–5 min for each array. Each force versus indentation curve was analyzed using an in-house
procedure (see supplementary material), which provided a cell elastic modulus (CEM) value to
characterize the local stiffness of the sample, with low CEM equaling low sample stiffness and
high CEM equaling high sample stiffness. Analysis of all force versus indentation curves and sub-
sequent algorithm application (see supplementary material) resulted in CEM-maps such as the one
shown in Fig. 1(a), and CEM probability distributions such as those shown in Figures 1(b) and S1
in the supplementary material. Typically, several thousand indentations were performed per biolog-
ical sample of which up to 1000 passed the quality test and were used for further analyses. Per bi-
ological sample, multiple CEM-maps were produced, from different individual cells and/or from
cells in a confluent monolayer, typically stemming from more than one well.
Micromesh-based cell separation
A scalable TFF device was produced from stainless steel and consisted of two mirror-
symmetric blocks of steel with S-shaped semicircular channels machined to a depth of 1mm into
the surface (Fig. 2). The shape of the channel was designed to maximize length and therefore sepa-
ration area of the device within the manufacturing and assembly constraints of our facilities. The
blocks were bolted together, separated by 8 lm nylon micromesh of approximate thickness 10 lm
and relative porosity of 0.27 (estimated in both cases from microscopy images) (MicroSievesTM,
BioDesign Inc., Carmel, NY), resulting in a cylindrical channel, 7 cm in length, divided into two
by mesh. The mesh division created the equivalent of channels 1 and 2 in our previously fabri-
cated Microchannel Separation Device (MSD) (supplementary material, Fig. S2 and Choudhury
et al., 2012), with flow and pressure driving forces across the mesh controlled by adjusting the liq-
uid flow rates above and below the mesh using microprocessor-controlled pumps. The channel
“above” the mesh is equivalent to a traditional TFF retentate flow and the channel “below” equiv-
alent to permeate. The dimensions of this device gave an effective separation area of 1.4 cm2, with
a maximum possible linear fluid velocity within the channel of 15 cm/s, constrained by the pumps
used. Flow rate conditions were chosen at 1.5ml/min into the device (channel 1, upper left input
in Fig. 2(b)) with the flowrate into the lower left input of channel 2 held at 0ml/min and the lower
right output of channel 2 controlled at 0.4ml/min. This resulted in a retentate flow (upper right
output, channel 1, Fig. 2(b)) of 1.1ml/min and a permeate volumetric flux (lower right channel,
Fig. 2(b)) of 0.4ml/min. These numbers were chosen based upon trial and error to provide reason-
able retentate and permeate flow rates to encourage any separation. Ideally, such a device would
be controlled by pressure drop across the membrane alone rather than flow rate, however this was
not possible in the current design. The flow rates chosen give a linear liquid velocity of 6.5 cm/s
above the membrane and 1.7 cm/s below the membrane, respectively, resulting in Reynolds num-
bers of 40 above and 11 below.
Cell separation
For all cell types, single cell suspensions were prepared using TrypLETM Express (Life
Technologies) and cell numbers quantified by hemocytometer. For cell separation experiments,
different cell populations were pooled in particular cell ratios to obtain an overall cell concen-
tration of approximately 1 106 cells/ml. Samples of feed material, permeate (that which has
passed through the mesh into an outlet channel), and retentate (that which remains in the main
channel) were collected for analysis. Flow rates through the mesh-based separation device
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(MBSD) were maintained at 1.5ml/min in channel 1 (above the mesh; retentate) and 0.4ml/
min in channel 2 (below the mesh; permeate) at all times. In each experiment, a 5ml suspen-
sion of cells in PBS (pH 7.2) was separated using the MBSD. As an example, cells in an ap-
proximate 1:1 mixture of hESCs and HDFs were at a total cell concentration of 0.96 106
cells/ml (range 0.8–1.1 106 cells/ml, n¼ 9 measurements from 3 runs). After the 5ml of cells
were passed through the device, a further 5ml of PBS was pumped into the feed inlet of the de-
vice to wash out any cells remaining in the channels into the retentate and permeate.
FIG. 1. Characterisation of cell stiffness for hESC and differentiated progeny using atomic force microscopy. Per cell type,
thousands of force versus indentation curves were acquired and analyzed by means of a computational analysis algorithm
(see supplementary material), ultimately providing a CEM (in kPa) value to characterize the stiffness of the cell population.
(a) Analysis (see supplementary material) of all force versus indentation curves resulted in elasticity CEM-maps such as
the one shown in the panel on the right-hand side, which is overlaid on an HDF cell preparation image on the left-hand
side. For each small square on the CEM-map, one force-indentation curve was measured in the center of the square. The
resulting color of the square represents the measured CEM value, i.e., stiffness, with darker colors indicating higher stiff-
ness. (b) Probability distributions of CEMs (as P(CEM)) generated through ordering the measured CEM values into bins of
equal width of 0.5 kPa. (c) Number of high-quality force-indentation curves used to extract CEM values and the median
CEM (in kPa) for the various cell types.
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Flow cytometry
Flow cytometry was performed on a FACSCalibur (Becton Dickinson) to assess cell type
representation within heterogeneous cell samples before and after separation. For the hESC/
HDF separation experiments, HDF were discriminated from hESCs using an antibody to CD13
(APC-conjugated mouse anti-human CD13, BD PharmingenTM; 1:1000 dilution) (Kahler et al.,
2013) and an appropriate isotype control. Depletion calculations were based on changes in num-
bers of CD13-positive cells in the various cell samples (feed, permeate, and retentate) following
separations. For the hESC/osteoblast separation experiments, the pluripotency associated surface
marker TRA-1-60 (PE-conjugated mouse anti-human TRA-1-60-R; Biolegend
VR
; 1:1000) and an
appropriate isotype control were used to identify hESCs, and osteoblast enrichment calculations
were based on changes in numbers of TRA-1-60 positive cells in feed and retentate.
Alizarin red staining
At various time points during differentiation of hESC-MP towards osteoblasts (days 1, 6,
11, 15, and 21), Alizarin red staining was used to assess the presence of calcium deposits. Cells
FIG. 2. Mesh-based separation device (MBSD). (a) Photograph of the S-shaped flow channel inside the MBSD after
removal of the mesh and top-half of the device. (b) Schematic of operation of the device drawn in vertical position, indicat-
ing the inlets for feed population (upper left) and medium (lower left), and outlets for the purified population (retentate,
upper right) and sorted population (permeate, lower right), in relation to the mesh dividing the channel. (c) Schematic of
the flow layout as duplicated in the top of and bottom half of the device, along with a channel cross section showing mem-
brane position.
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cultured in mTeSR1 medium (negative control) or under osteogenic differentiation conditions
on HA were washed twice with PBS, fixed with 95% methanol at room temperature, and
stained with Alizarin red S (10mg/ml) (Sigma) (10min, pH 4.2). After washing with water,
wells were inspected using light microscopy, and images taken for qualitative examination.
RESULTS
Assessment of cell stiffness using atomic force microscopy
Recently, we identified differences in cell stiffness between undifferentiated pluripotent
hESCs and terminally differentiated cells (HDFs) following measurements of limited samples
of cells by AFM (Kiss et al., 2011). Here, we first sought to compare stiffness of these two cell
types with that of hESC-MP cells as a surrogate intermediate cell type.
AFM measurements to determine stiffness (see Fig. 1 and supplementary material) were
carried out on individual cells of the following populations: an undifferentiated hESC line (H1-
hESC; at two different passage numbers, p65 and p68), a transgenic subclone of H1-hESC
containing a GFP reporter (H1-Oct4-EGFP cells), H1-hESC differentiated to a mesenchymal
progenitor (hESC-MP), and HDFs sourced from neonatal foreskin. For each cell type, several
thousand force versus indentation curves were acquired and analyzed (see supplementary mate-
rial). This analysis resulted in CEM-maps such as the one shown in Fig. 1(a). Next, probability
distributions of CEMs were determined by ordering the data into bins of equal width of 0.5 kPa
(Fig. 1(b) and supplementary material), ultimately providing a median CEM value (in kPa) to
characterize the stiffness of a given cell population (Fig. 1(c)), with a low CEM indicating low
stiffness and high CEM indicating high stiffness. Our data show that median CEMs of fully dif-
ferentiated cells are on average nearly three-fold higher than those of pluripotent (undifferenti-
ated) stem cells (i.e., differentiated cells are approximately three times as stiff) (Fig. 1(c)).
Stiffness-based cell separation
Although some degree of difference in median CEM between the cell types was anticipated
(Butt et al., 2005 and Kiss et al., 2011), the observed magnitudes offered the potential of using
elastic modulus as a cell separation tool for cells that are undifferentiated, terminally differenti-
ated, or in an intermediate state. To exploit this idea, we developed stiffness-based cell separa-
tion techniques to test feasibility. Previous efforts from our group had yielded a microfluidic
cell selection device containing 8lm wide channels (Choudhury et al., 2012). Based on optical
observation, this channel width was seen to reject most mammalian cells, presumably on a size
basis. However, preliminary experimental trials with the microfluidic device that involved quali-
tative monitoring of hESCs and HDFs via phase contrast and fluorescence microscopy showed
that cells with a sufficiently high degree of flexibility (i.e., a low CEM) were able to pass
through the separating channels to end up in the flow-through sample. To investigate this in
more detail, we developed our previously designed microfluidic separator further and fabricated
a MSD (Fig. S2 in the supplementary material) to ascertain the optimal design. Though the
MSD was able to separate mixed cell populations, due to size constraints this device only
allowed selection of a relatively small number of cells per run, precluding accurate quantifica-
tion of separation efficiency by means of flow cytometry. Analysis of separation was therefore
carried out by comparative optical and fluorescent microscopy, after flowing an approximate
50:50 mixture of fluorescent H1-Oct4-EGFP hESCs and HDFs into the device. Using our de-
vice to separate cells in this model system allowed us to observe Oct4-EGFP cells passing read-
ily through the narrow separating channels into channel 2 under green fluorescent illumination,
while the stiffer HDFs (higher CEM) remained in channel 1 (data not shown). Whilst compari-
son of videos under fluorescent and phase contrast conditions indicated efficient separation, our
inability to simultaneously video under fluorescence and phase contrast precluded direct quanti-
fication of separation efficiency.
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Micromesh-based cell separation
We next developed the MSD further into a larger, scalable, tangential flow cell separation
device. This new, MBSD was able to efficiently and accurately separate heterogeneous cell
populations (feed population; example average cell concentration 0.96 106 cells/ml (range
0.8–1.1 106 cells/ml, n¼ 9 measurements from 3 runs) into two distinct populations, namely,
a population enriched for cells unable to pass through the mesh (the “retentate”; example aver-
age cell concentration 0.82 106 cells/ml (range 0.77–0.92 106 cells/ml, n¼ 9 measurements
from 3 runs)) and a sorted population that separated from the former by passing through the
mesh (the “permeate”; example cell concentration 0.55 106 cells/ml (range 0.53–0.57 106
cells/ml, n¼ 9 measurements from 3 runs)). We have previously shown that cells passing
through microchannels of this size remain viable (as measured by propidium iodide and thiazole
orange comparative flow cytometry) (Choudhury et al., 2012). Figure 3 is a representative
example of flow cytometric analysis of feed, permeate, and retentate material corresponding to
the example data quoted above, showing that these three populations have a similar size profile
in Forward Scatter ((X-Axis; FSC)/side scatter (Y-Axis; SSC) dot plots, with FSC proportional
to cell size and SSC proportional to cell granularity/complexity (Figure 3, left column). After
running a mixture of H1-Oct4-EGFP cells and CD13-labelled HDFs through the MBSD, the
permeate contained considerably fewer HDFs compared to the feed population. HDFs were
reduced from 53.9% (range 51.0%–55.9%) in the feed population to 31.3% (range
31.1%–31.4%) in the permeate (n¼ 9 measurements from 3 runs) (exemplified by the contour
diagrams in Fig. 3, middle column). Conversely, the proportion of HDFs increased to 63.2%
(range 61.1%–64.1%) in the retentate (n¼ 9 measurements from 3 runs) (exemplified in Fig. 3,
contour diagrams). Our flow cytometry data indicate that the passage of hESCs through the
membrane is relatively unhindered, whilst HDFs are preferentially excluded. Overall loss of
cell number (based on total cell balance) in the device was negligible (total cells in feed:
4.0–5.5 106; total cells in retentate: 4.0–4.8 106; total cells in permeate: 0.93–1.0 106
(Fig. 3(d)); overall balance  100%, likely due to clumps of cells separating into single cells in
the device and slightly artificially inflating counts). Based on total cell numbers of each cell
type in the feed and the permeate, the separation shown in Fig. 3 represents a 44% relative
reduction in the permeate of the percentage of HDFs present in relation to H1-Oct4-EGFP cells
following a single pass, as calculated using the formula below:
Percentage HDF in Feed  PercentageHDF in Permeate
Percentage HDF in Feed
 
 100:
Experimental repeats consistently showed HDF removal of around 40% in a single pass for the
model H1-Oct4-EGFP/HDF cell system (range: 38.1%–44.4%; n¼ 9 samples from 3 runs).
Flow control enabled a relative 3:1 split in favor of the retentate in terms of volumetric flow
rate to ensure a pressure driving force across the membrane encouraging permeate flow. As this
device design did not include features for increasing turbulence and pressure-driving force as
would be seen in a traditional TFF cassette, there is considerable scope for further improvement
of separation efficiency and increased permeate flow rates relative to retentate flow.
Importantly, plotting the live gated cells as overlay FSC/SSC dot plots, with CD13-APC cells
in red (HDF) and Oct-4GFP cells in green (H1-Oct4 cells), shows enrichment/depletion of spe-
cific cell types in permeate and retentate without a change in size distribution profile (Fig. 3,
the right column).
Cell stiffness during osteoblast differentiation
Using our MBSD, we were thus able to separate heterogeneous cell populations into dis-
tinct populations based on CEM. To demonstrate that cell stiffness constitutes a reliable bio-
physical attribute varying with cell differentiation state of the same cell type, we next tried to
separate cells at various stages as they were being differentiated from their own progenitors.
For this, we used the well-established practice of directing osteogenesis of mesenchymal stem
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cells using a cocktail of reagents (Sottile et al., 2003). Osteogenic differentiation was carried
out with our mesenchymal-like cells hESC-MP over 21 days, with cell samples taken at regular
time points for Alizarin red staining to assess calcium content as proxy for cell mineralization,
and for AFM analyses to assess cell stiffness (Figs. 4 and S1 in the supplementary material).
The probability distribution curves in Figures 4 and S1 (supplementary material) illustrate
the typical variation in CEM as measured during differentiation of hESC-MPs towards
FIG. 3. Flow cytometric analysis of cells separated with MBSD. (a) In the left column, flow cytometric analysis of 5ml of
a 1:1 mixed population of H1-Oct4-EGFP cells and HDFs prior to separation (feed; top row) and following a single pass
through the MBSD (permeate cells; middle row, and retentate cells; bottom row) shows similarly sized populations in for-
ward scatter (X-Axis; FSC)/side scatter (Y-Axis; SSC) dot plots, with FSC proportional to cell size and SSC proportional
to cell granularity/complexity. In the middle column, gated live cells of these three cell populations have been plotted as
contour diagrams, with CD13-APC on the Y-Axis (HDFs) and Oct4-GFP on the X-axis (H1-Oct4-EGFPþ cells). These
plots show that a typical single pass cell separation resulted in a reduction of HDFs (in upper left quadrants) in permeate
compared to feed population from 55.9% to 31.2%, with a concurrent increase in HDFs in the retentate to 64.3%. Contour
lines in the four quadrants represent CD13-positive/Oct4-negative cells (upper left), Oct4-positive/CD13-positive cells
(upper right), Oct4-negative/CD13-negative cells (lower left), and Oct4 positive/CD13 negative cells (lower right). In the
right column, FSC/SSC dot plots of the live gated cells represent overlays of CD13-APC cells in red and Oct-4GFP cells in
green, showing enrichment/depletion of specific cell types in permeate and retentate without a change in size distribution
profile. (b) Tabulation of data presented in the middle column above, summarizing the reduction in HDF cells in permeate
compared to feed population from 55.9% to 31.2%—i.e., a 44% relative reduction, with a concurrent increase in HDFs in
the retentate to 64.3%—i.e., a 15% relative increase. Figures and table depict a representative example of 3 independent
separation experiments.
014107-9 Willoughby et al. Biomicrofluidics 10, 014107 (2016)
 This article is copyrighted as indicated in the article. Reuse of AIP content is subject to the terms at: http://scitation.aip.org/termsconditions. Downloaded to  IP:
129.215.87.150 On: Fri, 15 Jan 2016 09:38:46
osteoblasts. The general trend shows an increase in sample CEM during the early stages of differ-
entiation, i.e., an increase in cell stiffness. This is followed by a decrease in sample CEM (i.e., a
decrease in cell stiffness) between days 11 and 15, before another sharp increase in CEM is
observed at day 21. Thus, the median sample CEM appears to vary non-monotonously during the
differentiation process (Fig. 5). Interestingly, the CEM distribution at day 11 is bimodal with the
two probability maxima corresponding to those of day 6 and 15, respectively. This may indicate
that at this stage the cells transform relatively rapidly into a softer state. By day 15, essentially all
cells seem to have reached this state. The CEM distribution at day 21 is likewise bimodal with the
probability maximum at lower CEM corresponding to the single maximum of the day-15 CEM
distribution. The origin of the probability maximum at higher CEM is less clear. Alizarin red stain-
ing performed in parallel indicates increasing levels of mineralization in the culture wells over
time (Fig. 4). By day 21, the majority of the cells had become heavily mineralized. In addition,
crystals could be observed in the wells, which made the AFM difficult and may also have contrib-
uted to the stiffer responses. The lack of any population of “stiff” cells at day 15 as identified by
the CEM data indicates that the level of mineralization does not offer a complete explanation for
the bimodal distribution at day 21, and suggests that the cells may in fact become softer in
advance of mineralization, perhaps for flexibility or mobility reasons.
Separating osteoblasts from their precursor hESC-MPs using MBSD
The use of hESC-MP-derived osteogenic derivatives for reconstruction of bone constitutes
a clinical exemplar of a therapeutic approach requiring scaled production of cells and purifica-
tion thereof, which at present do not exist. To test MBSD’s utility for therapeutic cell
FIG. 4. Alizarin red staining and CEM probability distributions of hESCs undergoing osteogenic differentiation. hESC-MP
cells cultured in plates coated with Hyaluronan in medium supporting osteogenic differentiation show increasing calcifica-
tion over the course of differentiation, as assessed by alizarin red staining on the indicated days following the start of differ-
entiation (D1-6-11-15-21; photograph of stained wells on the right hand side). Cell presence in all wells was confirmed by
microscopic examination and subsequent stiffness measurements and sample imaging performed with AFM (data not
shown). Continuous probability distributions of CEM (P(CEM)) plotted against CEM in kPa (see supplementary material)
for the corresponding days are shown in the graphs to the left of the stained wells. The distributions demonstrate the pres-
ence of populations with higher CEM (i.e., higher stiffness) at day 6, 11, and 21.
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production, we collected hESC osteolineage derivatives at various days post-initiation of differ-
entiation and mixed them 1:1 with TRA-1-60-R-PE-labelled hESCs for subsequent separation,
analogous to our hESC/HDF experiments (feed population; example average cell concentration
1.19 106 cells/ml (range 1.14–1.22 106 cells/ml, n¼ 3 measurements of single-pass separa-
tion); retentate; example average cell concentration 0.73 106 cells/ml (range 0.67–0.83 106
cells/ml, n¼ 3 measurements of single-pass separation); and permeate; example cell concentra-
tion 0.91 106 cells/ml (range 0.83–1.0 106 cells/ml, n¼ 3 measurements of single-pass sepa-
ration). Overall loss of cell number (based on total cell balance) in this scenario was less than
9% (total cells in feed: 5.7–6.1 106; total cells in retentate: 3.5–4.35 106; total cells in per-
meate: 1.6–1.75 106; overall balance>91%).
In this case, we measured for enrichment of osteoblastic lineages by assessing depletion of
hESCs. Calculating the percentage of cells expressing pluripotency marker TRA-1-60 in feed
(for example, day 11, percentage hESCs 44.9%6 5.4%, n¼ 3 from a single-pass separation)
and retentate (for example, day 11, percentage hESCs 30.4%6 1.4%, n¼ 3 from a single-pass
separation), we observed that the level of enrichment of stiffer osteoblastic (calculated as level
of depletion of hESCs in the same manner as described earlier) cells in the retentate sample
increases with increasing CEM (i.e., increased stiffness) of the differentiating cells during the
first 15 days (Fig. 5); (for example, day 11, enrichment in osteoblastic cells of 32.2%6 6.8%,
n¼ 3 from single-pass separation), suggesting that the device is using stiffness as the main sep-
aration parameter.
DISCUSSION
The present study defines differences in the stiffness between pluripotent human embryonic
stem cells and derivative mesenchymal and terminally differentiated osteoblast-like cells and
dermal fibroblasts, based on atomic force microscopy measurements. This information was
exploited to develop a cell separation device containing a woven mesh, employing tangential
flow filtration separation principles. The device allowed for rapid yet gentle, label-free, and
FIG. 5. CEM versus cell separation achievement over the course of hESC osteogenesis. Variations in median CEM (in
kPa; Y-axis on the left) of hESC-MP cells undergoing osteogenesis, as measured at various time points post initiation of
differentiation (on X-axis), are plotted in relation to relative enrichment (in %; right Y-axis) of pluripotent hESCs achieved
in the retentate after running 5ml of an hESC/osteoblast mixed cell population through the MBSD device once at the indi-
cated days during differentiation. Over time, the cells’ stiffness increases, peaking at day 6 (high kPa), after which the me-
dian CEM indicates a lower sample stiffness (day 11), and average low stiffness comparable with that of hESC at day 15.
Enrichment calculations are based on changes in the numbers of cells expressing pluripotency marker TRA-1-60 in feed
and permeate, with bars indicating the extent of dataset range. From day 1 till day 15, stiffness corresponds with enrich-
ment, in that higher stiffness of the osteoblasts mixed in with the hESC resulted in higher enrichment of the soft hESCs in
the permeate.
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scalable passive cell selection, prospectively amenable to automatable and high-throughput cell
purification to meet future industrial and clinical demands for human pluripotent stem cell
based advanced therapy medicinal products.
The growth and differentiation potential of human stem cells make them a promising
source of cells for regenerative medicine. The development of effective and economical systems
to select or purify pluripotent stem cells and derivatives thereof in ways that are reproducible,
free of operator biases, non- or minimally invasive (including label-free), rapid, and scalable
will ultimately dictate the extent of human pluripotent stem cell-based applications in regenera-
tive medicine cell therapy. Currently, mammalian cell purification largely depends on binding
of cell surface ligands as applied in fluorescent-activated flow cytometric- or magnetic-bead
based sorting. However, these methods rely on knowledge about ligand expression, and subse-
quent availability and specificity of complementary probes, as well as on skilled personnel. In
addition, probes will remain in the sample and probably even associated with the cell after seg-
regation, potentially affecting cell state, with unknown consequences for the patient who will
receive the cell preparation. Finally, as these platforms sort on a cell-by-cell basis in a fluid
flow or column of limited cross dimensions, which limits the throughput and therefore the scal-
ability of the techniques, these ligand-recognising selection methods in their current form do
not provide automated, scalable strategies for stem cell purification. The device used in the cur-
rent study constituted a prototype suitable for separation of cells for analysis with further work
required to incorporate and validate design features to assure maintenance of sterility so that
separated cells can be subsequently cultivated or used for industrial or therapeutic applications.
Ideally, such a device would be “closed” to the external environment and constructed as an
affordable single use disposable product.
Cell separation based on cell biophysical properties like size, shape, surface charge, and
cell stiffness is still comparatively underexplored. Reports describing separation of various cell
types based on their stiffness have been produced mainly in the fields of infectious diseases and
cancer research and diagnostics. For example, recent papers describe microfluidics methods to
separate healthy red blood cells from diseased ones (e.g., sickle cell anaemia (Kose et al.,
2009) and malaria infection (Hou et al., 2010)), and benign from cancerous cells (e.g., breast
cancer (Hou et al., 2009), circulating tumour cells from blood (Hur et al., 2011), and epithelial
cancer cells mixed with white blood cells (Wang et al., 2013)). Recently, we suggested that
stiffness could also serve as the basis of a simple and efficient purification technique to discrim-
inate subpopulations of hESC (Kiss et al., 2011). Using AFM, we and others have previously
demonstrated effective measurements of cell stiffness for a variety of cell types, including
human embryonic (Kiss et al., 2011), mouse embryonic (Pillarisetti et al., 2011), and adult
mesenchymal stem cells (Bongiorno et al., 2014), and a variety of human cell lines (Wang
et al., 2013), and we applied this tool in our current study as well. We defined cell stiffness as
CEM, which varies depending on the cell’s function, fate, and lineage commitment. CEM is
primarily determined by the presence, number, and distribution of specific organelles (e.g., nu-
cleus and mitochondria) and the character and organisation of cytoskeletal elements (e.g.,
microfilaments, microtubules, and intermediate filaments) (Becker and Gard, 2006 and Yoon
et al., 2002). Thus, parameters for isolation of different cell types, for example, chondrocytes
(stiff; high CEM) and fibroblasts (less stiff; lower CEM) will differ widely (Butt et al., 2005).
Similarly, metastatic cancer cells are softer than their “parental” cell type, likely to allow defor-
mation and subsequent extravasation (Cross et al., 2007 and Remmerbach et al., 2009), support-
ing the notion that changes in stiffness likely reflect physiological adaptation for specific tasks,
in this case enhanced migration through tissues. Cell stiffness can also change significantly dur-
ing cell differentiation, as we report herein for osteogenic derivatives of stem cells, and as has
previously been shown for a variety of cell types, including stem cells, myocytes, and myeloid
cells by us (Kiss et al., 2011) and others (Bongiorno et al., 2014; Collinsworth et al., 2002,
Ekpenyong et al., 2012; Pillarisetti et al., 2011; Titushkin and Cho, 2007, Yourek et al., 2007,
and Yu et al., 2010), with undifferentiated cells being softer (i.e., having a lower CEM) than
their differentiated progeny. Indeed, mechanical property of cells has been proposed as a
marker of differentiation state for stem cells (Darling et al., 2008 and Kiss et al., 2011).
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Moreover, cell stiffness has recently been proposed as a predictive marker for multipotency and
differentiation potential of adipose-derived stem cell clones (Gonzalez-Cruz et al., 2012) and
bone-marrow-derived mesenchymal stromal cells (Lee et al., 2014).
We recently reported on the design and fabrication of a robust microfluidics device capable
of separating a heterogeneous population of cells with variable degree of stiffness into enriched
populations (Choudhury et al., 2012). Here, we describe a mesh-based label-free TFF cell sepa-
ration device where the level of enrichment of soft, pluripotent hESCs in a mixed cell popula-
tion made up of hESCs and derivative osteolineage cells correlated with the stiffness of the dif-
ferentiating derivatives. Thus, the stiffer the progeny cells, the more effectively they were
separated from the softer progenitors in the feed population after a single pass through the de-
vice. These data strongly suggest that the device is using cell stiffness as a major separation pa-
rameter, and that differentiation-induced cell stiffness can form the basis of an efficient, label-
free device for the separation of stem cells and their progeny. The data for day 21, however,
deviated somewhat, with a relatively low enrichment percentage in spite of high median CEM.
We hypothesize that this result is indicative of the biological process involved in the formation
of osteoblastic lineages in cell culture plates. On both day 11 and day 21, a clear bimodal dis-
tribution of elastic modulus can be seen in Fig. 4. On day 11, we postulate this is because the
population contains a number of stiffer cells (similar to those at day 6) and a number of softer
cells (similar to those at day 15). However, we do not think that the cells are becoming stiffer
again on day 21. Rather, we postulate that while the majority of cells are soft (as those at day
15), extensive mineralisation surrounding the cells biases the AFM measurements causing the
cells to appear stiffer than they truly are. In suspension, however, a degree of dissociation
between the cells and the mineralization is likely to occur, releasing a cell population which is
in fact softer than the AFM data indicate. Consequently, a less efficient separation from the
similarly soft hESCs, and thus a lower enrichment, is achieved.
This variation in elastic modulus and separation efficiency during the differentiation pro-
cess emphasizes an important point regarding manufacture of cell therapy products. Purification
should not necessarily be considered as an “end-of-process” operation to obtain the desired dif-
ferentiated product, but rather be informed by the changing biophysical properties evidently
occurring during the course of the differentiation process. Combined with the fact that the con-
taminating cells of most concern are those that do not differentiate but remain pluripotent, it
may be beneficial to preferentially select for a cell type mid-way through a production process,
when physical properties of targets and contaminants differ to the highest degree, and then
allow the differentiation to continue post-selection.
Our study has not discriminated the relative contributions of other biophysical parameters
such as cell size, shape, and charge with the potential to impact on separation efficiency in
addition to cell deformability, although our flow cytometry results do clearly show that cell size
is not a key separation factor. By using membrane pore cut-off sizes smaller than the minimum
diameter of any cell in the system, we sought to reduce the prospective contribution of cell size
and shape as cell separation parameters. Furthermore, on day 15, where the larger osteoblastic
cells and the smaller hESCs have comparable median CEM, hardly any enrichment was
observed, suggesting that size effects may not dominate elasticity effects. However, given the
broad and overlapping CEM distribution profiles assessed by AFM in our study, most probably
reflecting cellular heterogeneity resulting from spontaneous or asynchronous differentiation, it
may be necessary to incorporate other separation parameters, such as charge, shape, and size, in
order to efficiently discriminate different cell types.
The device demonstrated here is a first-pass proof-of-principle device and accordingly is
not optimized for fluid mechanic effects. A volumetric flux of 0.4ml/min through a membrane
area of 1.4 cm2 represents an average flux rate of approximately 170 l/m2h, which is relatively
low for such a large pore size of membrane and could clearly be improved. Similarly, whilst no
measurement of pressure drop across the membrane could be taken in the current device design,
pressure drop can be estimated after the fact from flux rates using a modified Hagen-Poiseulle
equation as shown below
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J ¼ DPd
2e
32xl
;
where J is the volumetric flux, DP is the pressure drop, d is the pore diameter, e is the relative
porosity of the membrane, x is the pore length (in this case membrane thickness), and l is the
fluid viscosity. Operating conditions used during the experimental work presented here indicate
an average pressure drop across the membrane around 1 Pa (calculated from the above formula),
again very low for a filter of any kind.
The relatively low liquid flowrates chosen result in sub-optimal liquid velocities for mixing,
and accordingly result in low Reynolds numbers. However, given the sensitivity of the target
cells, flow conditions that minimize shear are crucial. A balance must be achieved between low
shear and improved mixing. Given the low Reynolds numbers seen here it is very likely that,
as the cells passing above the membrane will be constrained by streamline flow, many will not
pass close to the membrane thus limiting the efficiency of separation per pass. Improving the
flow patterns in the device to increase relative cell/membrane interaction, increase membrane
driving force (pressure drop), and therefore increase flux should improve the level of separation
per pass and hence the efficiency of the device, but this optimisation must be carried out in
conjunction with computational fluid dynamic analysis and shear studies to ensure cell viability.
This optimisation forms a separate body of future work, and the data here are presented simply
to demonstrate the potential of separation via elastic properties. Though the data presented here
are based on a non-optimised device, it is nevertheless clear that, with levels of removal
approaching 50% in a single pass, our device represents a promising method for label-free puri-
fication of cells for clinical applications. The current device was run with a relative 3:1 volu-
metric flow rate ratio in favour if the retentate over the permeate, resulting in a reduction in
total permeate cell numbers in the permeate relative to volumetric flow. Coupled with the
reduced permeate flow rate, total numbers of cells in the permeate are around 5–10 fold lower
than those in the retentate. This indicates that, whilst the device is effective at specific selection
under these conditions, resulting in enriched permeate populations, both the selectivity and the
overall flux of cells through the membrane could be optimized further to produce purer reten-
tate and permeate populations and, potentially more crucially, an improved permeate yield if
required through increased permeate flow rate. Separation performance of the device will be
affected by a number of factors above and beyond hydrodynamic flow effects, including relative
cell concentrations in the feed population and the mesh pore size in relation of the separated
species. Improving the level of separation achieved in a single pass will be a key design
improvement for moving from the proof-of-principle shown here to a more commercially rele-
vant separation device. Further investigation of effects of pore size and cell type ratios in feed
(containing an order of magnitude fewer pluripotent cells than our model systems) along with
optimization of turbulence and pressure driving force, shear levels, residence time, and fluid
flow conditions represent the next stage in the engineering design of this unit operation.
Within the current device design, it is highly likely that recycling (multiple pass separation)
would improve the level of separation, however given the relative lack of understanding of the
hydrodynamic environment it would unwise to speculate on the possible level of improved
enrichment in this scenario. Rather, our future focus is on optimising single pass enrichment
before considering recycling/multiple pass scenarios.
Some other filter-based label-free separation systems record higher purity levels, e.g., close
to 99% for leukocyte depletion using normal flow filtration (NFF) (Sethu et al., 2006) and
>95% for red blood cell removal using TFF (Chen et al., 2008), though the latter required rig-
orous sample dilution. In a direct comparison of NFF, TFF, and Weir- and Pillar-based flow fil-
tration for sorting human blood, TFF outperformed the other three filter systems by showing an
average efficiency of >70%–80% of trapping white blood cells and passing red blood cells
(Ji et al., 2008). Recently, Li et al. (2014) developed a cell sorting chip for processing whole
blood, combining TFF with a microfiltration membrane, that could recover 27% of white blood
cells with 94% purity. Using a dielectrophoresis-based device for separation of stem cells and
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their differentiation progeny (osteoblasts), Song et al. (2015) achieved a collection efficiency of
up to 92% and 67% for stem cells and osteoblasts, with a purity of up to 84% and 87%, respec-
tively. Reported separation devices for human cell separation, however, focus on low-
throughput applications, typically performing in the ll/min (Ji et al., 2008; Sethu et al., 2006;
and Song et al., 2015) to ml/h range (Li et al., 2014 and Zhang et al., 2012) and depending on
the underlying methodology, may encounter scaling difficulties. Our device was able to main-
tain a permeate flow rate of 0.4ml/min and process in the order of 5 106 cells/min through an
effective separation area of only 1.4 cm2. Since the principle behind our device described herein
is broadly similar to TFF, a unit operation which is routinely scaled up for industrial applica-
tions including culturing bacterial, insect, and antibody-producing mammalian cells (van Reis
and Zydney, 2001 and Reynolds et al., 2003), scalability is not envisaged to be a hurdle for our
device. Specifically, given that larger scale commercially available TFF unit cassettes can be 10
m2 in membrane area or higher, and that TFF separation scales are reasonably predictable with
increasing membrane surface area, it is entirely reasonable to assume that our technique, with
optimisation of flow parameters within larger scale membrane devices, would be able to scale
up to permeate flow rates of several tens of litres per minute and process cell numbers well in
excess of 1011 cells/min.
In conclusion, we have designed and validated a novel device permitting the physical sepa-
ration of undifferentiated and differentiating/differentiated human embryonic stem cells based
on their stiffness. In the future, the evolution of this technology should benefit the purification
of stem cells and their derivatives. This should improve the efficiency and safety of industrial
and therapeutic applications that require them.
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